Session

IBD (Posters)

NUTRITIONAL STATUS AND DISEASE ACTIVITY IN CROHN'S DISEASE: PRELIMINARY DATA
NUTRITIONAL STATUS AND DISEASE ACTIVITY IN CROHN'S DISEASE: PRELIMINARY DATA

PRELIMINARY EXPERIENCE IN MAINTENANCE TREATMENT WITH INTRAVENOUS USTEKINUMAB AS A RESCUE FOR LOSS OF RESPONSE TO SUBCUTANEOUS DOSES
PRELIMINARY EXPERIENCE IN MAINTENANCE TREATMENT WITH INTRAVENOUS USTEKINUMAB AS A RESCUE FOR LOSS OF RESPONSE TO SUBCUTANEOUS DOSES

GRANULOCYTE AND MONOCYTE APHERESIS IS AN EXCELLENT CHOICE AS AN ADJUNCTIVE THERAPY TO INDUCE AND MAINTAIN REMISSION IN ULCERATIVE COLITIS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
GRANULOCYTE AND MONOCYTE APHERESIS IS AN EXCELLENT CHOICE AS AN ADJUNCTIVE THERAPY TO INDUCE AND MAINTAIN REMISSION IN ULCERATIVE COLITIS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

TREATMENT OPTIONS IN IBD PATIENTS IN ROUTINE CLINICAL PRACTICE IN RUSSIA, KAZAKHSTAN, AND BELARUS - INTERIM ANALYSIS OF THE INTENT STUDY
TREATMENT OPTIONS IN IBD PATIENTS IN ROUTINE CLINICAL PRACTICE IN RUSSIA, KAZAKHSTAN, AND BELARUS - INTERIM ANALYSIS OF THE INTENT STUDY

ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH CLINICAL, BIOLOGICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN_S DISEASE
ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH CLINICAL, BIOLOGICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN_S DISEASE

CHANGE IN THE EXPRESSION OF SERPIN E1, A POTENTIAL NEW DISEASE ACTIVITY MARKER, REFLECTS THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASE
CHANGE IN THE EXPRESSION OF SERPIN E1, A POTENTIAL NEW DISEASE ACTIVITY MARKER, REFLECTS THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASE

IMPACT OF ANTI-TNF-? AGENTS ON MACROPHAGES RESPONSE TO ADHERENT-INVASIVE ESCHERICHIA COLI INFECTION IN PATIENTS WITH CROHN'S DISEASE
IMPACT OF ANTI-TNF-? AGENTS ON MACROPHAGES RESPONSE TO ADHERENT-INVASIVE ESCHERICHIA COLI INFECTION IN PATIENTS WITH CROHN'S DISEASE

ANTI-TNF SERUM CONCENTRATIONS ARE ASSOCIATED WITH ENDOSCOPIC REMISSION IN CROHN_S DISEASE
ANTI-TNF SERUM CONCENTRATIONS ARE ASSOCIATED WITH ENDOSCOPIC REMISSION IN CROHN_S DISEASE

ONTAMALIMAB(-S) BLOCKS INFLAMMATORY BOWEL DISEASE T CELL ADHESION AND AMELIORATES T CELL-DEPENDENT COLITIS IN VIVO
ONTAMALIMAB(-S) BLOCKS INFLAMMATORY BOWEL DISEASE T CELL ADHESION AND AMELIORATES T CELL-DEPENDENT COLITIS IN VIVO

REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS
REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS

MADCAM-1 ANTAGONISM WITH ONTAMALIMAB PROMOTES DRAINAGE OF LEUKOCYTES IN VITRO THROUGH THE INTESTINAL LYMPHATIC ENDOTHELIUM FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE
MADCAM-1 ANTAGONISM WITH ONTAMALIMAB PROMOTES DRAINAGE OF LEUKOCYTES IN VITRO THROUGH THE INTESTINAL LYMPHATIC ENDOTHELIUM FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE

HOSPITAL RE-ADMISSIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE- WHAT ARE THE RISK FACTORS?
HOSPITAL RE-ADMISSIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE- WHAT ARE THE RISK FACTORS?

THE GUT MICROBIOME OF HEALTHY SIBLINGS OF INFLAMMATORY BOWEL DISEASE (IBD) TWINS DISPLAYS IBD SIGNATURES
THE GUT MICROBIOME OF HEALTHY SIBLINGS OF INFLAMMATORY BOWEL DISEASE (IBD) TWINS DISPLAYS IBD SIGNATURES

IMPROVEMENT OF INTESTINAL ULTRASOUND PARAMETERS WITHIN 12 WEEKS AFTER TREATMENT INDUCTION IN CD AND UC PATIENTS - FIRST INTERIM ANALYSIS OF THE TRUST BEYOND STUDY
IMPROVEMENT OF INTESTINAL ULTRASOUND PARAMETERS WITHIN 12 WEEKS AFTER TREATMENT INDUCTION IN CD AND UC PATIENTS - FIRST INTERIM ANALYSIS OF THE TRUST BEYOND STUDY

MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND EVALUATION OF THERAPEUTIC RESPONSE
MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND EVALUATION OF THERAPEUTIC RESPONSE

IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

GUT MICROBIAL CHANGES IN RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
GUT MICROBIAL CHANGES IN RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

DIETARY INTAKE IS ASSOCIATED WITH FLARE DEVELOPMENT IN IBD PATIENTS
DIETARY INTAKE IS ASSOCIATED WITH FLARE DEVELOPMENT IN IBD PATIENTS

THIOPURINE THERAPY IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE: ADVERSE EVENTS AND THIOPURINE METABOLITES
THIOPURINE THERAPY IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE: ADVERSE EVENTS AND THIOPURINE METABOLITES

TREATMENT PATTERNS AMONG PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE RECEIVING BIOLOGIC THERAPY IN FRANCE, GERMANY AND THE UNITED KINGDOM
TREATMENT PATTERNS AMONG PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE RECEIVING BIOLOGIC THERAPY IN FRANCE, GERMANY AND THE UNITED KINGDOM

Item 221 - 240 / 558
1 2 3 4 5 6 7 8 9 10 11
12
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28